Moraga-Espinoza DF - Search Results

1

Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.

Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, Smyth HDC. Bahamondez-Canas TF, et al. Among authors: moraga espinoza df. J Pharm Sci. 2018 Aug;107(8):2172-2178. doi: 10.1016/j.xphs.2018.04.015. Epub 2018 Apr 24. J Pharm Sci. 2018. PMID: 29698726

2

Inhaled Biologics: From Preclinical to Product Approval.

Fathe K, Ferrati S, Moraga-Espinoza D, Yazdi A, Smyth HD. Fathe K, et al. Curr Pharm Des. 2016;22(17):2501-21. doi: 10.2174/1381612822666160210142910. Curr Pharm Des. 2016. PMID: 26861725 Review.

3

Mass Median Plume Angle: A novel approach to characterize plume geometry in solution based pMDIs.

Moraga-Espinoza D, Eshaghian E, Smyth HDC. Moraga-Espinoza D, et al. Int J Pharm. 2018 May 30;543(1-2):376-385. doi: 10.1016/j.ijpharm.2018.04.008. Epub 2018 Apr 7. Int J Pharm. 2018. PMID: 29635056

4

A modified USP induction port to characterize nasal spray plume geometry and predict turbinate deposition under flow.

Moraga-Espinoza D, Warnken Z, Moore A, Williams RO 3rd, Smyth HDC. Moraga-Espinoza D, et al. Int J Pharm. 2018 Sep 5;548(1):305-313. doi: 10.1016/j.ijpharm.2018.06.058. Epub 2018 Jun 27. Int J Pharm. 2018. PMID: 29960037

5

Effect of Inhalation Flow Rate on Mass-Based Plume Geometry of Commercially Available Suspension pMDIs.

Moraga-Espinoza DF, Eshaghian E, Shaver A, Smyth HDC. Moraga-Espinoza DF, et al. AAPS J. 2018 Jul 12;20(5):84. doi: 10.1208/s12248-018-0241-6. AAPS J. 2018. PMID: 30003443

6

In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.

Tewes F, Bahamondez-Canas TF, Moraga-Espinoza D, Smyth HDC, Watts AB. Tewes F, et al. Eur J Pharm Biopharm. 2020 Jul;152:210-217. doi: 10.1016/j.ejpb.2020.05.014. Epub 2020 May 20. Eur J Pharm Biopharm. 2020. PMID: 32442738 Free article.

7

Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process.

Gallegos-Catalán J, Warnken Z, Bahamondez-Canas TF, Moraga-Espinoza D. Gallegos-Catalán J, et al. Pharmaceutics. 2021 Jul 9;13(7):1051. doi: 10.3390/pharmaceutics13071051. Pharmaceutics. 2021. PMID: 34371741 Free PMC article. Review.

8

Formulation of water-soluble Buddleja globosa Hope extracts and characterization of their antimicrobial properties against Pseudomonas aeruginosa.

Araya N, Leiva-Soto MA, Bruna MV, Castro-Munoz A, Behrend-Keim B, Moraga-Espinoza D, Bahamondez-Canas TF. Araya N, et al. Front Pharmacol. 2022 Nov 10;13:921511. doi: 10.3389/fphar.2022.921511. eCollection 2022. Front Pharmacol. 2022. PMID: 36438832 Free PMC article.

9

The forgotten material: Highly dispersible and swellable gelatin-based microspheres for pulmonary drug delivery of cromolyn sodium and ipratropium bromide.

Behrend-Keim B, Castro-Muñoz A, Monrreal-Ortega L, Ávalos-León B, Campos-Estrada C, Smyth HDC, Bahamondez-Canas TF, Moraga-Espinoza D. Behrend-Keim B, et al. Int J Pharm. 2023 Sep 25;644:123331. doi: 10.1016/j.ijpharm.2023.123331. Epub 2023 Aug 18. Int J Pharm. 2023. PMID: 37597595

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters